Contraindicated (one)bortezomib will boost the degree or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or moderate CYP2C19 inhibitors may possibly maximize mavacamten systemic publicity, causing coronary heart failure as a result of systolic dysfunction. Inform your medical professional For anyone who is Expecting or plan to https://kirko333qbm6.eedblog.com/profile